Search results

Recent years have seen acquisitions become a common element of any growth strategy for multinationals engaged in China's pharmaceutical market.  At least half of the top 10 multinationals in China appear to be actively pursuing one or more targets with...

47Kb

In this edition, we focus on off-label drug use and promotion, and provide a comparative analysis of China's legal regime with other jurisdictions in Europe and the US. In addition to our lead article, we have included two further legal updates on Good...

In August 2011, China issued new provisions for its national security review system. These provisions cover procedure and reflect MOFCOM's latest instructions on the process and timeline for submitting applications for national security review, and should...

To promote direct foreign investment and in line with the policy of the National Development and Reform Commission (NDRC), the Shanghai government issued an opinion in April to delegate further its verification and approval authority. The opinion is good news for...

In this edition, we focus on antitrust issues, consider some of the challenges facing companies, and examine the enforcement trends in China. We also include three industry insight articles and two further articles on key developments in the regulatory...

In this second of two articles exploring the impact of China's antitrust regime on the pharmaceutical industry, we consider in more detail how the day-to-day operations of pharmaceutical companies are affected by China's competition regime, and highlight...

Selected regulatory changes April – June 2011 (English & Chinese)

In the first of two articles on the impact on pharmaceutical companies of China's antitrust regime, we focus on the changing shape of merger control review.

In this edition, we have included two articles in our Industry Insights section and five on what we see as key developments in the regulatory environment. We also include a link to a comprehensive round up of regulatory changes at the end of this bulletin.